Mayer L, Fu S M, Kunkel H G
Immunol Rev. 1984 Apr;78:119-35. doi: 10.1111/j.1600-065x.1984.tb00479.x.
Human T cell hybridomas were generated by several techniques and the supernatants generated were screened for activity on human B cells. Three general activities were noted; B cell proliferation factor ( BCPF ), B cell differentiation factor (BCDF), and an IgA isotype-specific helper factor. BCPF acts on B cells to induce proliferation without differentiation and is distinct from conventional BCGF. This was documented by BCPF 's inability to synergize with anti-mu Ab in a standard BCGF assay ( Muraguchi & Fauci 1982, Howard et al. 1982, Sieckman et al. 1981), as well as its differential effect on a leukemic B cell preparation, when compared with BCGF. A possible schema for BCPF activity is depicted in Figures 3 and 4. In Figure 3, BCPF acts like Ag in vivo or like anti-mu in vitro, pre-activating B cells and rendering them responsive to BCGF. Figure 4 represents what our data depict, that is that BCPF bypasses the response to BCGF and induces cells to proliferate without pre-activation. The difference in the 2 mechanisms may be concentration-dependent and this possibility is currently being evaluated. It is interesting to speculate that T cells in vivo are capable of initiating B cell activation and may account for polyclonal responses seen with some Ag-specific reactions. BCDF(s) act on post-activated B cells (Figure 3) to induce differentiation to Ig-secreting cells. They appear to be heterogeneous and, therefore are capable of inducing varied responses depending on the B cell subpopulation affected. Figure 3 is deliberately complex demonstrating some of the possible as well as documented BCDF activities including polyclonal differentiation and isotype specific activity in IgA committed B cells. We cannot be certain of the frequency of these BCDF-secreting T cells, but the studies of cells from patients with common variable immunodeficiency and chronic lymphocytic leukemia have helped to dissect out these activities. These data would suggest that these BCDF subgroups are important, as deficiencies in one or more subgroups may result in disease.
通过多种技术生成了人T细胞杂交瘤,并对所产生的上清液进行筛选,以检测其对人B细胞的活性。发现了三种一般活性;B细胞增殖因子(BCPF)、B细胞分化因子(BCDF)和一种IgA同种型特异性辅助因子。BCPF作用于B细胞以诱导增殖而不诱导分化,并且不同于传统的BCGF。这在标准BCGF测定中BCPF无法与抗μ抗体协同作用(村口和福西,1982年;霍华德等人,1982年;西克曼等人,1981年)以及与BCGF相比,其对白血病B细胞制剂的不同作用中得到了证明。图3和图4描绘了BCPF活性的一种可能模式。在图3中,BCPF在体内的作用类似于抗原,在体外类似于抗μ抗体,预先激活B细胞并使其对BCGF产生反应。图4代表了我们的数据所描述的情况,即BCPF绕过对BCGF的反应并诱导细胞在未预先激活的情况下增殖。这两种机制的差异可能取决于浓度,目前正在对此可能性进行评估。有趣的是推测体内的T细胞能够启动B细胞活化,并且可能解释了在一些抗原特异性反应中看到的多克隆反应。BCDF作用于活化后的B细胞(图3)以诱导其分化为分泌Ig的细胞。它们似乎是异质性的,因此能够根据受影响的B细胞亚群诱导不同的反应。图3有意设计得很复杂,展示了一些可能的以及已记录的BCDF活性,包括多克隆分化和在IgA定向B细胞中的同种型特异性活性。我们无法确定这些分泌BCDF的T细胞的频率,但对常见可变免疫缺陷和慢性淋巴细胞白血病患者细胞的研究有助于剖析这些活性。这些数据表明这些BCDF亚群很重要,因为一个或多个亚群的缺陷可能导致疾病。